Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) EBIT Margin: 2011-2025

Historic EBIT Margin for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to 38.01%.

  • Adma Biologics' EBIT Margin rose 493.00% to 38.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.19%, marking a year-over-year increase of 417.00%. This contributed to the annual value of 32.59% for FY2024, which is 2421.00% up from last year.
  • Adma Biologics' EBIT Margin amounted to 38.01% in Q3 2025, which was up 8.32% from 35.08% recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' EBIT Margin ranged from a high of 38.01% in Q3 2025 and a low of -94.49% during Q1 2021.
  • Its 3-year average for EBIT Margin is 23.39%, with a median of 30.38% in 2025.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 13,250bps in 2021, then plummeted by 149bps in 2025.
  • Over the past 5 years, Adma Biologics' EBIT Margin (Quarterly) stood at -23.98% in 2021, then spiked by 1,186bps to -12.12% in 2022, then surged by 3,138bps to 19.26% in 2023, then surged by 1,334bps to 32.60% in 2024, then soared by 493bps to 38.01% in 2025.
  • Its last three reported values are 38.01% in Q3 2025, 35.08% for Q2 2025, and 30.38% during Q1 2025.